StemCell Therapy

Data Bridge Market Research analyses that thecataract treatment marketwill exhibit a CAGR of around 5.00% for the forecast period of 2022-2029. Growing demand for targeted mode of therapies, surge in the research and development activities for the development of noveldrugsand therapies, increasing programmes by government and non-profit organizations to reduce the burden of cataract-related diseases worldwide and increased expenditure for the development ofhealthcareinfrastructure are the major factors attributable to the growth of cataract treatment market.

Cataract is an eye related disorder wherein one suffers blurry vision due to clouding of lens in the eye. Cataract slowly leads to decrease in the vision ability and in some cases even loss of vision. In this medical condition, the protein, that form the lens of an eye get clumped down.

Get a Sample PDF of the report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cataract-treatment-market

This cataract treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on cataract treatment market contact Data Bridge Market Research for anAnalyst Brief,our team will help you take an informed market decision to achieve market growth.

Global Cataract Treatment Market Scope and Market Size

The cataract treatment market is segmented on the basis of type, treatment, drugs class, drugs, route of administration, distribution channel and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

To Gain More Insights into the Market Analysis, Browse Summary of the Research [emailprotected] https://www.databridgemarketresearch.com/reports/global-cataract-treatment-market

Cataract Treatment Market Country Level Analysis

The cataract treatment market is analysed and market size insights and trends are provided by country, type, treatment, drugs class, drugs, route of administration, distribution channel and end user as referenced above. The countries covered in the cataract treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the cataract treatment market owing to the earliest adoption of innovative technologies, growing research and development capacities and well-structured regulatory framework. Asia-Pacific is projected to undergo substantial gains during the forecast period and score the highest CAGR. This is because of the rising expenditure to develop healthcare infrastructure, increasing health care spending, rising prevalence of cataract disorders, favourable regulations and increasing personal disposable income.

The country section of the cataract treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Cataract Treatment Market Share Analysis

The cataract treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to cataract treatment market.

The major players operating in the cataract treatment market report are Abbott, Johnson & Johnson Services, Inc, Novartis AG, HOYA Corporation, Carl-Zeiss-Stiftung, Alcon Vision LLC, Essilor, Ziemer Ophthalmic Systems, Bausch Health, GENZUM LIFE SCIENCES, AbbVie Inc, Santen Pharmaceutical Co., Ltd, Omeros Corporation, Sun Pharmaceutical Industries Ltd, EyePoint Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Acumen BioPharma, LLC, Takeda Pharmaceutical Company Limited, AstraZeneca and F. Hoffmann-La Roche Ltd among others.

Browse the complete table of contents at https://www.databridgemarketresearch.com/toc/?dbmr=global-cataract-treatment-market

Related Reports:

Allogenic Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-allogenic-stem-cell-therapy-market

Cancer Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-cancer-stem-cell-therapy-market

North America Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/north-america-stem-cell-therapy-market

Europe Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/europe-stem-cell-therapy-market

Asia-Pacific Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/asia-pacific-stem-cell-therapy-market

Middle East and Africa Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/middle-east-and-africa-stem-cell-therapy-market

Asia-Pacific Drug-Device Combination Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-drug-device-combination-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:-[emailprotected]

View original post here:
Cataract Treatment Market Trends, Drivers and Growth Projection Up to 2029 Alcon Vision LLC, Essilor, Ziemer Ophthalmic Systems, Bausch Health,...

DUBLIN--(BUSINESS WIRE)--The "Hunter Syndrome Treatment Market Analysis by Treatment (Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT)), and by Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global hunter syndrome treatment market size is estimated to be USD 995.71 million in 2021 and is expected to witness a CAGR of 7.83% during the forecast period.

Increase in number of patients suffering from hunter syndrome is a key driver for the growth of the global hunter syndrome treatment market.

Additionally, the rise in initiatives taken up by the governments, introduction of novel therapies in the market, and occurrence of strong pipeline portfolio are some of the other drivers propelling the market growth.

Nevertheless, the increasing cost of treatment and lack of awareness about hunter syndrome treatment are expected to restrain the global market growth.

The hunter syndrome treatment market report is categorized into the following segments and subsegments:

By Treatment (Revenue, USD Million, 2021-2029)

By Region (Revenue, USD Million, 2021-2029)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/gtd8tm

The rest is here:
Global Hunter Syndrome Treatment Market Analysis to 2026 - Focus on Hematopoietic Stem Cell Transplant (HSCT) and Enzyme Replacement Therapy (ERT) -...

COLOGNE, Germany, July 14, 2022 (GLOBE NEWSWIRE) -- Maleth Program is the first space bioscience project led by Professor Joseph Borg of the University of Malta. The second mission under the Maleth Program, or Maleth II, was launched on the July 15th, 2022.

Visit link:
Singleron supports Project Maleth’s second mission MALETH II by analyzing biological samples sent to space

PRESS RELEASE - INSIDE INFORMATION

Read more here:
Bone Therapeutics optimizes statistical analysis and introduces interim analysis in the ongoing ALLOB Phase IIb study for high-risk tibial fractures

Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. To recover these headwinds, substantial price increases will be implemented.

More:
Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost

ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR     15 JULY 2022 at 11.00 EEST

Read more:
Orion Corporation's financial reporting and Annual General Meeting in 2023

HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies

Read the original:
HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

ORION CORPORATION        HALF-YEAR FINANCIAL REPORT 1–6/2022        15 JULY 2022 at 12:00 EEST

Read the original post:
Orion Group Half-Year Financial Report 1–6/2022

STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company’s Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. (“AbbVie”) until his retirement last year, brings over 30 years of experience in global commercial strategy and operations.

Read the original:
SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

REHOVOT, Israel, July 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that the Company, the Employees’ Union of Kamada’s Beit Kama production facility in Israel, and the Histadrut - General Federation of Labor in Israel, signed a new collective agreement detailing the understandings reached between the parties. The agreement will be effective through the end of 2029, while certain economic terms may be renegotiated by the parties following the lapse of the first four years of the term of the agreement.

See the original post:
Kamada Announces Resolution to the Labor Strike at the Company’s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed

RESEARCH TRIANGLE PARK, N.C., July 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 1st Annual Hereditary Angioedema Virtual Conference on Wednesday, July 20, 2022, at 10:00 a.m. ET.

Continue reading here:
BioCryst to Present at Upcoming Investor Conference

SIGA to Supply TPOXX® to Support KaliVir’s Oncolytic Vaccinia Clinical Immunotherapy Program SIGA to Supply TPOXX® to Support KaliVir’s Oncolytic Vaccinia Clinical Immunotherapy Program

Original post:
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every ten (10) shares of common stock, effective as of 12:01 a.m. (Eastern Time) on July 25, 2022 (the “Effective Date”). The Company’s common stock will begin trading on a split-adjusted basis when the market opens on July 25, 2022. The reverse stock split was authorized by the Company’s Board of Directors on July 11, 2022. Pursuant to the laws of the State of Nevada, the Company’s state of incorporation, the Company’s Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company’s common stock will continue to trade on the NYSE American under the stock ticker “SYN” but will trade under the new CUSIP number 87164U409.

Read more from the original source:
Synthetic Biologics Announces Reverse Stock Split

ESTERO, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- Marijuana Strategic Ventures, Inc. (the “Company”) (OTC: MSVI) announces updates to the progress of its three areas of focus: Health, Innovation and Research & Development.

Continue reading here:
Marijuana Strategic Ventures, Inc. (OTC: MSVI) Announces Updates for Mushrooms, Inc., Health Product Production, Provisional Patent and Business Plan...

On Track for FY 2022 Guidance

Link:
CENTOGENE Reports First Quarter 2022 Financial Results

Endo affiliate, Paladin Labs, will commercialize Quoin’s lead asset for Netherton Syndrome in Canada Endo affiliate, Paladin Labs, will commercialize Quoin’s lead asset for Netherton Syndrome in Canada

Go here to read the rest:
Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements

IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders regarding progress in the Company business activities. Nymox wishes to assure our shareholders that business plans are continuing to be developed and are on track. The Company will provide regular and further specific details when there is upcoming material information available to share. In the meantime, ongoing initiatives are continuing and are being positively advanced.

Read the original here:
NYMOX Updates Shareholders

PRESS RELEASE

See more here:
Notice of extraordinary general meeting in Saniona AB

COPENHAGEN, Denmark, July 15, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox.

Read the rest here:
U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that the Board of Directors has accepted the voluntary resignation of Dr. Kunwar Shailubhai as Chief Executive Officer, Chief Scientific Officer and Board director, effective as of August 1, 2022. Dr. Shailubhai resigned for personal reasons, and his resignation is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Read more:
Tiziana Life Sciences Announces Resignation of CEO